LeukoSight Inc. is an early stage biotechnology company developing a novel line of therapeutics that can be used to treat autoimmune and inflammatory diseases. LeukoSight’s technology promises to offer safe, convenient, and more effective treatment options for these debilitating diseases.
LeukoSight’s therapeutic platform is directed at treating the most prominent of autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. These diseases represent an enormous health-care burden, with over 3 million Americans suffering from these diseases, and many more world-wide. LeukoSight is developing a line of recombinant molecules with potent immunoregulatory activity. The anti-inflammatory effects of these therapeutics makes them good candidates to treat a variety of acute and chronic inflammatory diseases.